Alliance Pharma PLC Notification of Half Year Results (7459K)

TIDMAPH

RNS Number : 7459K

Alliance Pharma PLC

06 September 2021

 
 For immediate release                                              6 September 2021 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Notification of Half Year Results,

Results Presentation and Analyst Call

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the six months ended 30 June 2021 on Tuesday 21 September 2021.

A link to a recorded presentation of the half year results, by Peter Butterfield, Chief Executive Officer, and Andrew Franklin, Chief Financial Officer, will be included in the results announcement.

The recorded presentation will also be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors/ .

A Q&A call for analysts will be held at 10.00am on the day of the results, 21 September 2021; analysts who require joining details should contact Buchanan at [e-mail] .

For any further information, please contact Buchanan at the details below.

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 [e-mail] 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Duncan Monteith 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                  + 44 (0)20 7597 5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

More information on Alliance can be found on our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSSSFMDEFSEDU

(END) Dow Jones Newswires

September 06, 2021 02:00 ET (06:00 GMT)